{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:16:51Z","timestamp":1774084611342,"version":"3.50.1"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201400002C"],"award-info":[{"award-number":["HHSO100201400002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n            We have evaluated the activity of meropenem-vaborbactam against clinical isolates of\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            <jats:italic>and<\/jats:italic>\n            <jats:named-content content-type=\"genus-species\">Acinetobacter baumannii<\/jats:named-content>\n            in a neutropenic mouse thigh infection model. Data show that meropenem-vaborbactam regimens equivalent to 3-h infusions every 8\u2009h with 2\u2009g meropenem and 2\u2009g vaborbactam produced bacterial killing against strains with MICs of 2 to 16\u2009mg\/liter and suggests that this combination may have utility in the treatment of infections caused by\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">A. baumannii<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.01665-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T10:53:04Z","timestamp":1539687184000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-0262","authenticated-orcid":false,"given":"Mojgan","family":"Sabet","sequence":"first","affiliation":[{"name":"The Medicines Company, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziad","family":"Tarazi","sequence":"additional","affiliation":[{"name":"The Medicines Company, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Griffith","sequence":"additional","affiliation":[{"name":"The Medicines Company, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/320183"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00127"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Kaye KS Vazquez J Mathers A Daikos G Alexander E Loutit JS. 2017. Clinical outcomes of serious infections due to carbapenem-resistant Enterobacteriaceae (CRE) in TANGO II a phase 3 randomized multi-national open-label trial of meropenem-vaborbactam versus best available therapy. Abstr 1862 IDWeek San Diego CA.","DOI":"10.1093\/ofid\/ofx163.1392"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00843-15"},{"key":"e_1_3_2_8_2","volume-title":"Abstr","author":"Tarazi Z","year":"2015","unstructured":"Tarazi Z, Sabet M, Rubio-Aparicio D, Sun D, Nolan T, Parkinson J, Lomovskaya O, Griffith DC. 2015. Efficacy of simulated human exposures of meropenem compared to Carbavance\u2122 (meropenem-RPX7009) against Pseudomonas aeruginosa in an in vitro hollow fiber model. Abstr 25th ECCMID, Copenhagen, Denmark."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2017.09.001"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01446-17"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01439-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02228-17"},{"key":"e_1_3_2_15_2","volume-title":"Guide for the care and use of laboratory animals","author":"Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council","year":"1996","unstructured":"Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC."},{"key":"e_1_3_2_16_2","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing, 24th in formational supplement ed","author":"Clinical and Laboratory Standards Institute (CLSI","year":"2014","unstructured":"Clinical and Laboratory Standards Institute (CLSI). 2014. Performance Standards for Antimicrobial Susceptibility Testing, 24th in formational supplement ed Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.23.8.988.32878"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/590064"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Bhavnani SM Trang M Griffith DC Lomovskaya O Hammel JP Loutit JS Dudley MN Ambrose PG Rubino CM. 2017. Vaborbactam pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses as support for dose selection in patients with normal renal function and varying degrees of renal impairment. Abstr 1852 IDWeek San Diego CA.","DOI":"10.1093\/ofid\/ofx163.1382"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01665-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01665-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:19:51Z","timestamp":1645478391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01665-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1128\/AAC.01665-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01665-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"2018-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01665-18"}}